Physician

Charles Walter Debrosse, M.D.

According to 2025 Medicare claims, Charles Debrosse, M.D. (NPI: 1700043155) practices allergy/immunology in the Dayton-Kettering-Beavercreek, OH market, with the plurality of this provider's patient population coming from Montgomery, OH. This provider's primary affiliated billing organization is OHIO ALLERGY ASSOCIATES, INC. (NPI: 1962489435; TIN: 311426084) and primary practice location at 45458-1877.

Debrosse's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 368 traditional Medicare patients, billed 20,514 HCPCS/CPT codes, and received $357,644 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,580 prescription claims across 334 beneficiaries totaling $762,600 in drug costs, led by Xolair (Omalizumab). DME data shows 295 claims. Open Payments data shows 84 records totaling $46,827. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $33,016 to $357,644. Similarly, Part D prescription costs have moved sharply higher in recent years, from $135,762 to $762,600. In contrast, DME billing represents a smaller volume and rose steadily, from $838 to $8,566.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	151	3,078	$33,016
2016	172	3,304	$35,211
2017	202	4,418	$44,390
2018	180	3,553	$37,858
2019	192	4,402	$46,262
2020	204	4,036	$38,770
2021	227	5,473	$50,809
2022	192	4,395	$44,981
2023	310	4,971	$51,992
2024	368	20,514	$357,644

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	138	602	$135,762
2016	144	667	$165,860
2017	142	633	$139,419
2018	161	720	$163,746
2019	182	833	$183,965
2020	170	838	$227,111
2021	204	918	$315,491
2022	231	1,089	$588,459
2023	262	1,189	$691,814
2024	334	1,580	$762,600

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	52	$6,628
2016	N/R	N/R	N/R
2017	N/R	16	$77
2018	N/R	N/R	N/R
2019	N/R	47	$20,134
2020	N/R	122	$80,791
2021	N/R	152	$125,205
2022	N/R	182	$586,626
2023	N/R	192	$673,928
2024	N/R	295	$769,195

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	155	252	$87
94010	Test to measure expiratory airflow and volume	66	81	$19
95165	Professional service for preparation and provision of 1 or more antigens	83	1,106	$8
95117	Professional service for multiple injections of allergen	92	1,315	$8
96160	Administration and interpretation of patient-focused health risk assessment	90	131	$2

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xolair	Omalizumab	56	1,568	$149,745
Tezspire	Tezepelumab-Ekko	19	588	$89,439
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	100	4,200	$86,639
Dupixent Pen	Dupilumab	14	448	$58,452
Gammaked	Immune Globul G/Gly/Iga Avg 46	16	448	$49,318

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J1554	Injection, immune globulin (asceniv), 500 mg	N	N/R	30	$462,313
J1559	Injection, immune globulin (hizentra), 100 mg	N	N/R	57	$244,294
J1558	Injection, immune globulin (xembify), 100 mg	N	N/R	13	$49,008
A4221	Supplies for maintenance of non-insulin drug infusion catheter, per week (list drugs separately)	N	N/R	67	$5,346
Q2052	Services, supplies and accessories used in the home for the administration of intravenous immune globulin (ivig)	N	N/R	16	$5,274

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	84	$46,827	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Charles Walter Debrosse, M.D.?

Tedicare shows public-source Medicare data for Charles Walter Debrosse, M.D. (NPI 1700043155), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Charles Walter Debrosse, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Charles Walter Debrosse, M.D.?

Charles Walter Debrosse, M.D. is linked to OHIO ALLERGY ASSOCIATES, INC. (billing NPI 1962489435) in the available physician profile data.

Does Charles Walter Debrosse, M.D. have Open Payments data?

Charles Walter Debrosse, M.D. has 84 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.